Michael A. Singer

Diana V. Do, MD, speaks with Michael A. Singer, MD, about findings from the NEW DAY trial of sustained-release fluocinolone acetonide vs aflibercept. The following transcript has been edited for clarity. Diana V. Do, MD: Hi, I'm joined by Michael A. Singer, MD. Tell us about your exciting new data on steroids and sustained release for the treatment of retinal vascular diseases. Michael A. Singer, MD: Diana, it’s always great talking to you.

Anthropic, until Friday’s White House move, looked like one of the more rationally valued companies in its peer group [Weiterlesen]

Myopia progression in children has emerged as one of the most pressing concerns in modern ophthalmology, with prevalence rising sharply across East Asian populations and increasingly worldwide. For retinal specialists and comprehensive ophthalmologists alike, the window for meaningful intervention is narrow—and the demand for effective, patient-friendly treatment options has never been greater.